CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma